| |
DIABHYCAR
|
SURDIAGENE
|
|---|
|
No events
|
Cardiovascular events
|
No events
|
Cardiovascular events
|
|---|
|
T1
|
873 (84.4%)
|
161 (15.6%)
|
339 (72.3%)
|
130 (27.7%)
|
|
T2
|
841 (81.3%)
|
193 (18.7%)
|
309 (65.9%)
|
160 (34.1%)
|
|
T3
|
808 (78.4%)
|
223 (21.6%)
|
246 (52.4)
|
223 (47.6%)
|
| |
HR (95% CI)
|
p
|
HR (95% CI)
|
p
|
|---|
|
Model 1
|
|
T3 vs T1
|
1.40 (1.13–1.72)
|
0.001
|
2.10 (1.68–2.64)
|
< 0.0001
|
|
T2 vs T1
|
1.28 (1.04–1.59)
|
0.02
|
1.46 (1.15–1.85)
|
0.002
|
|
T3 vs T2
|
1.09 (0.90–1.33)
|
0.39
|
1.44 (1.18–1.78)
|
0.0005
|
|
Loge[copeptin]
|
1.21 (1.06–1.37)
|
0.004
|
1.52 (1.37–1.67)
|
< 0.0001
|
|
Model 2
|
|
T3 vs T1
|
1.29 (1.04–1.59)
|
0.02
|
1.58 (1.23–2.04)
|
0.0004
|
|
T2 vs T1
|
1.25 (1.01–1.54)
|
0.04
|
1.39 (1.10–1.77)
|
0.006
|
|
T3 vs T2
|
1.03 (0.85–1.26)
|
0.75
|
1.14 (0.91–1.43)
|
0.27
|
|
Loge[copeptin]
|
1.13 (0.99–1.29)
|
0.06
|
1.28 (1.12–1.46)
|
0.0003
|
- Data expressed as number of cases and (%) by line. Hazards ratio (HR) computed by Cox proportional hazards survival regression analysis for tertiles of plasma copeptin, and for 1 unit of loge[copeptin]. Model 1: adjusted for sex, age, BMI, duration of diabetes, systolic blood pressure, arterial hypertension, HbA1c, total cholesterol, HDL-cholesterol, triglycerides, active tobacco smoking, and previous history of myocardial infarction at baseline. In DIABHYCAR, analysis was further adjusted for study treatment (randomization group in the original DIABHYCAR study: ramipril vs placebo) during follow-up. Model 2: model 1 plus adjustments for eGFR and UAC at baseline. p < 0.05 is significant
